PCa predominantly depends on androgen signaling for survival and growth, making androgen deprivation therapy, combined with androgen receptor (AR)-targeting agents such as abiraterone acetate or enzalutamide, the standard first-line treatment for metastatic PCa [3]. Here, AR is linked to posterior cortical atrophy.